Exact Sciences Corporation found using ticker (EXAS) now have 15 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 226 and 140 with the average target price sitting at 162.13. Now with the previous closing price of 155.01 this would indicate that there is a potential upside of 4.6%. The 50 day MA is 141.48 and the 200 day moving average is 113.43. The market capitalisation for the company is $26,034m. Visit the company website at: http://www.exactsciences.com
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company’s pipeline products focuses on the research and development of enhancing Cologuard’s performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.